Periotherapia

The company's core business is the research and development of drugs targeting this pathological periostin. Its primary focus is on an antibody drug for metastatic and recurrent HER2-negative breast cancer, including the particularly aggressive triple-negative breast cancer (TNBC), which disproportionately affects younger women and has a five-year survival rate below 50%. The business model centers on advancing its drug candidates through non-clinical and early clinical trials with the aim of achieving early approval and then potentially partnering with larger pharmaceutical companies for commercialization. A key element of their strategy involves the parallel development of companion diagnostics to identify patients with high expression of pathological periostin, which is intended to increase the success rate of clinical trials.

Periotherapia has developed a pipeline of therapeutic neutralizing antibodies that specifically target and suppress the abnormal activity of pathological periostin. This targeted approach is designed to act only in specific pathological environments, thereby minimizing side effects on healthy tissues. The company has built a robust intellectual property portfolio with numerous patents to protect its unique technology. Through a series of funding rounds, including Series A, B, C, and D, and support from entities like the Japan Agency for Medical Research and Development (AMED), the company has secured capital to advance its clinical trials in Japan and prepare for trials in the U.S. A significant milestone was the initiation of a clinical trial for their lead antibody, PT0101, at Osaka University Hospital in March 2025. The company also has a joint research agreement with Eisai Inc.